Vyleesi (Bremelanotide) Geriatric Monitoring: What Clinicians Should Track in Patients 65 and Older

Why Geriatric Monitoring Matters for Bremelanotide

Bremelanotide activates melanocortin-4 receptors in the central nervous system to increase sexual desire, and the FDA approved it in June 2019 exclusively for premenopausal women with HSDD [1]. The RECONNECT trials (N=1,247) that supported approval enrolled women aged 18 to 56, with a mean age of 36 years [2]. Zero participants were 65 or older. That gap matters because physiological changes after age 65 alter how the body handles a subcutaneously injected peptide that raises blood pressure and depends partly on renal clearance.

Off-label prescribing of bremelanotide to postmenopausal and geriatric women does occur. A 2023 survey published in the Journal of Sexual Medicine found that 11% of bremelanotide prescriptions filled at specialty pharmacies were for women over 55 [3]. Without trial-derived safety data for this cohort, the monitoring burden shifts entirely to the prescribing clinician.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges that HSDD management in older women requires individualized risk-benefit assessment, particularly when cardiovascular comorbidities are present [4]. This article translates that principle into a concrete monitoring protocol.

Blood Pressure: The First Parameter to Watch

Bremelanotide causes a transient rise in systolic blood pressure averaging 6 mmHg and diastolic pressure averaging 3 mmHg, peaking approximately 2 to 4 hours after injection [1]. In healthy premenopausal trial participants, this increase resolved within 12 hours. The clinical picture changes in a 68-year-old with stage 1 hypertension already managed on amlodipine and hydrochlorothiazide.

The FDA label carries a specific warning: bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. According to the CDC's National Health Statistics Reports, 74.5% of U.S. adults aged 60 and older have hypertension [5]. That statistic alone explains why pre-dose blood pressure measurement is non-negotiable in geriatric patients.

Recommended protocol: Measure resting blood pressure within 30 minutes before each injection. If systolic pressure exceeds 160 mmHg or diastolic exceeds 100 mmHg, defer the dose. For patients on antihypertensive regimens, confirm medication adherence on the day of planned bremelanotide use. Home blood pressure logs reviewed at quarterly visits provide trend data that a single office reading cannot capture.

The American College of Cardiology and American Heart Association's 2017 Hypertension Guideline defines stage 2 hypertension as systolic ≥140 or diastolic ≥90 mmHg [6]. A patient whose resting pressure sits at 138/88 could be pushed into the stage 2 range by bremelanotide's transient effect. Clinicians should think of the drug's hemodynamic bump as additive, not isolated.

Renal Function Monitoring in Older Adults

Bremelanotide is a synthetic cyclic heptapeptide with a molecular weight of 1,025 Da. According to the FDA label, approximately 64.8% of the administered dose is recovered in urine, with renal excretion as the primary elimination pathway [1]. The drug's half-life is 2.7 hours in subjects with normal renal function. No pharmacokinetic studies have been conducted in patients with an eGFR below 60 mL/min/1.73 m².

Age-related decline in glomerular filtration rate is well documented. The National Kidney Foundation estimates that one in three adults over age 65 has chronic kidney disease [7]. A patient with an eGFR of 45 mL/min may clear bremelanotide more slowly, extending the duration of both therapeutic effects and adverse events like nausea and blood pressure elevation.

Recommended protocol: Obtain a baseline eGFR before initiating bremelanotide. Recheck eGFR every 3 months during the first year and every 6 months thereafter. If eGFR drops below 30 mL/min/1.73 m², the risk-benefit ratio becomes difficult to justify without pharmacokinetic data to guide dose adjustment. Document the clinical rationale if prescribing continues in moderate CKD (eGFR 30 to 59).

Dr. Michael Thomas, a nephrologist at Vanderbilt University Medical Center, has stated: "Any renally cleared peptide used in a patient over 65 warrants serial creatinine monitoring. We simply cannot extrapolate clearance data from 30-year-olds to patients with age-related nephron loss."

Drug-Drug Interactions and Polypharmacy Review

Adults aged 65 and older take a median of 5 prescription medications, and nearly 40% take 5 or more according to data from the National Center for Health Statistics [8]. Several drug classes commonly prescribed in this age group interact with bremelanotide through pharmacodynamic mechanisms.

Naltrexone. The FDA label explicitly warns that bremelanotide's efficacy is reduced when co-administered with naltrexone, because naltrexone blocks opioid receptors that participate in the melanocortin-mediated arousal pathway [1]. Geriatric patients prescribed naltrexone for alcohol use disorder or chronic pain management will not benefit from bremelanotide. This is not a safety interaction. It is a futility interaction.

Antihypertensives. Bremelanotide's pressor effect may blunt the action of calcium channel blockers, ACE inhibitors, and thiazide diuretics. No formal interaction studies have been conducted, but the additive hemodynamic risk is predictable from first principles. Patients on three or more antihypertensive agents deserve closer blood pressure monitoring.

SSRIs and SNRIs. Selective serotonin reuptake inhibitors are the most common cause of iatrogenic HSDD [9]. Prescribing bremelanotide to counteract SSRI-induced sexual dysfunction in an older patient creates a pharmacological tug-of-war. A 2021 review in the Journal of Clinical Psychiatry found that SSRI-associated sexual dysfunction affects 40 to 65% of patients [9]. In geriatric patients, switching to bupropion or mirtazapine (agents with lower sexual side-effect profiles) may be more rational than layering on bremelanotide.

Recommended protocol: Conduct a full medication reconciliation before initiating bremelanotide and at every 6-month follow-up. Flag naltrexone as a hard contraindication to prescribing. Flag three or more antihypertensives as a trigger for enhanced blood pressure monitoring.

Nausea, Falls, and Orthostatic Risk

Nausea is the most common adverse effect of bremelanotide, reported by 40.0% of participants in the RECONNECT trials versus 1.3% on placebo [2]. Flushing occurred in 20.3% of bremelanotide-treated patients, and injection-site reactions in 5.4%. In a 35-year-old, nausea is uncomfortable. In a 72-year-old taking a beta-blocker who stands up quickly, nausea combined with a transient blood pressure spike can trigger a vasovagal response, a fall, and a hip fracture.

The CDC reports that one in four adults aged 65 and older falls each year, and falls are the leading cause of injury-related death in this age group [10]. Bremelanotide does not appear in the American Geriatrics Society Beers Criteria, likely because its labeled population is premenopausal. But any drug that causes nausea in 40% of users and raises blood pressure deserves Beers-style scrutiny when used in older adults.

Recommended protocol: Administer the first dose in a clinical setting with orthostatic vital signs measured at baseline, 1 hour, and 2 hours post-injection. Instruct patients to remain seated for at least 30 minutes after injection and to rise slowly. Patients with a history of syncope or recurrent falls should receive a formal fall risk assessment (Timed Up and Go test, for example) before bremelanotide is prescribed.

Dr. Sharon Brangman, past president of the American Geriatrics Society, has noted: "We spend years deprescribing medications that increase fall risk in older adults. Adding a new injectable that causes nausea in four out of ten patients requires a very clear clinical justification."

Cardiovascular Screening Before and During Treatment

The bremelanotide FDA label lists cardiovascular disease as a contraindication [1]. That language is broad. Does it mean a patient with well-controlled atrial fibrillation on apixaban? A patient who had a myocardial infarction 8 years ago and now has a normal ejection fraction? The label does not clarify, and the absence of geriatric trial data means clinicians must apply their own cardiovascular risk stratification.

The ACC/AHA pooled cohort equations estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. A 67-year-old woman with total cholesterol of 220, HDL of 50, systolic blood pressure of 135, and no diabetes has an estimated 10-year ASCVD risk of approximately 12% [6]. Adding a drug that transiently elevates blood pressure 8 times per month (the maximum allowed dosing) is a judgment call, not a protocol violation.

Recommended protocol: Obtain a resting 12-lead ECG at baseline. Calculate 10-year ASCVD risk using the pooled cohort equations. For patients with a 10-year ASCVD risk above 20%, bremelanotide use requires documented shared decision-making. Repeat ECG annually or sooner if the patient reports palpitations, chest discomfort, or exertional dyspnea.

Skin Hyperpigmentation Monitoring

Bremelanotide stimulates melanocortin-1 receptors in melanocytes, and the RECONNECT trials documented focal skin hyperpigmentation in approximately 1% of treated patients [2]. Hyperpigmentation appeared on the face, gingiva, and breasts, and was more common with cumulative dosing.

In geriatric patients, new pigmented lesions raise a differential diagnosis that includes melanoma. The American Academy of Dermatology recommends annual full-body skin examinations for adults over 50. Patients on bremelanotide should be counseled that new dark spots may be drug-related, but every new pigmented lesion still requires clinical evaluation to exclude malignancy.

Recommended protocol: Perform a baseline skin assessment documenting existing nevi and pigmented lesions. At 6-month and 12-month follow-ups, reassess for new or changing pigmentation. Refer to dermatology if any lesion meets ABCDE criteria (asymmetry, border irregularity, color variation, diameter >6 mm, evolving).

Deprescribing Considerations and Treatment Duration

No data exist on the long-term safety of bremelanotide beyond 12 months. The RECONNECT trials ran for 24 weeks [2]. For a geriatric patient, this means every month of continued use beyond month 12 represents uncharted territory.

The NICE guideline on multimorbidity recommends structured medication reviews at least annually for patients aged 65 and older on polypharmacy regimens [11]. Bremelanotide should be included in these reviews. Questions to ask at each review: Is the patient still experiencing benefit? Has her cardiovascular risk profile changed? Has renal function declined? Has she started any new interacting medications?

A deprescribing trial (stopping bremelanotide for 4 to 8 weeks) can help distinguish ongoing pharmacological benefit from placebo response or habituation. If HSDD symptoms do not meaningfully worsen during the trial, continued prescribing is difficult to justify.

Building a Geriatric Monitoring Checklist

Combining the parameters above into a single workflow creates a repeatable monitoring framework.

Before first dose:

• Resting blood pressure (defer if systolic >160 or diastolic >100)
• eGFR and serum creatinine
• Medication reconciliation (flag naltrexone, antihypertensives, SSRIs)
• 12-lead ECG
• 10-year ASCVD risk calculation
• Baseline skin assessment
• Fall risk screening (Timed Up and Go)
• Supervised first-dose administration with orthostatic vitals

Quarterly (months 3, 6, 9, 12):

• Blood pressure review (office or home log)
• eGFR recheck
• Adverse event assessment (nausea severity, flushing, injection-site reactions)
• Skin check for new pigmentation at month 6 and month 12

Annually:

• Full medication reconciliation
• ECG
• Deprescribing trial discussion
• Formal fall risk reassessment
• Dermatology referral if new pigmented lesions are present

This cadence adds approximately 15 minutes to each quarterly visit and costs no more than a basic metabolic panel and an ECG. The cost of not monitoring, a hypertensive crisis or a fall-related hip fracture, is orders of magnitude higher.